Perspective Therapeutics (NYSE:CATX) Given “Buy” Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Perspective Therapeutics (NYSE:CATX) in a research note published on Monday morning,Benzinga reports. HC Wainwright currently has a $10.00 price objective on the stock.

Several other research firms have also commented on CATX. Wedbush reiterated an “outperform” rating and issued a $11.00 price objective on shares of Perspective Therapeutics in a research note on Wednesday, March 26th. Cantor Fitzgerald raised Perspective Therapeutics to a “strong-buy” rating in a research report on Tuesday, March 4th. Brookline Capital Management raised Perspective Therapeutics to a “strong-buy” rating in a research report on Monday, March 10th. Scotiabank began coverage on Perspective Therapeutics in a research note on Friday, March 7th. They issued a “sector outperform” rating and a $15.00 price objective for the company. Finally, Royal Bank of Canada lowered their target price on Perspective Therapeutics from $16.00 to $15.00 and set an “outperform” rating on the stock in a research note on Thursday, March 27th. One analyst has rated the stock with a hold rating, eight have issued a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $14.44.

Perspective Therapeutics Trading Down 3.2 %

NYSE CATX opened at $2.13 on Monday. The company has a fifty day moving average price of $2.91 and a 200-day moving average price of $6.19. Perspective Therapeutics has a 1 year low of $2.01 and a 1 year high of $19.05.

Hedge Funds Weigh In On Perspective Therapeutics

Several large investors have recently modified their holdings of CATX. FMR LLC lifted its stake in shares of Perspective Therapeutics by 3,994.9% during the 3rd quarter. FMR LLC now owns 5,504,822 shares of the company’s stock valued at $73,489,000 after buying an additional 5,370,392 shares in the last quarter. Janus Henderson Group PLC lifted its position in shares of Perspective Therapeutics by 8.0% during the third quarter. Janus Henderson Group PLC now owns 4,799,352 shares of the company’s stock worth $64,014,000 after acquiring an additional 355,685 shares in the last quarter. Deerfield Management Company L.P. Series C lifted its position in shares of Perspective Therapeutics by 4.3% during the fourth quarter. Deerfield Management Company L.P. Series C now owns 2,938,754 shares of the company’s stock worth $9,375,000 after acquiring an additional 120,991 shares in the last quarter. Octagon Capital Advisors LP boosted its holdings in shares of Perspective Therapeutics by 62.1% in the fourth quarter. Octagon Capital Advisors LP now owns 2,304,752 shares of the company’s stock worth $7,352,000 after acquiring an additional 882,528 shares during the period. Finally, State Street Corp grew its position in shares of Perspective Therapeutics by 119.6% in the third quarter. State Street Corp now owns 2,190,239 shares of the company’s stock valued at $29,240,000 after purchasing an additional 1,192,812 shares in the last quarter. Hedge funds and other institutional investors own 54.66% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.